Thromboelastography - Revision history

Mikael Häggström: SIze

2024-04-11T21:20:54Z

SIze

← Older revision		Revision as of 17:20, 11 April 2024
Line 4:		Line 4:
	}}		}}
	==Interpretation==		==Interpretation==
	[[Image:Thromboelastography parameters.png\|thumb\|~~300px~~\|Normal thromboelastogram with parameters.]]		[[Image:Thromboelastography parameters.png\|thumb\|330px\|Normal thromboelastogram with parameters.]]
	Parameters derived from thromboelastography are mainly:<ref name="pmid32988649">{{cite journal\| author=Tyler PD, Yang LM, Snider SB, Lerner AB, Aird WC, Shapiro NI\| title=New Uses for Thromboelastography and Other Forms of Viscoelastic Monitoring in the Emergency Department: A Narrative Review. \| journal=Ann Emerg Med \| year= 2021 \| volume= 77 \| issue= 3 \| pages= 357–366 \| pmid=32988649 \| doi=10.1016/j.annemergmed.2020.07.026 \| pmc= \| doi-access=free }} </ref>		Parameters derived from thromboelastography are mainly:<ref name="pmid32988649">{{cite journal\| author=Tyler PD, Yang LM, Snider SB, Lerner AB, Aird WC, Shapiro NI\| title=New Uses for Thromboelastography and Other Forms of Viscoelastic Monitoring in the Emergency Department: A Narrative Review. \| journal=Ann Emerg Med \| year= 2021 \| volume= 77 \| issue= 3 \| pages= 357–366 \| pmid=32988649 \| doi=10.1016/j.annemergmed.2020.07.026 \| pmc= \| doi-access=free }} </ref>
	* '''R time''': Time to initial clot formation (that is, amplitude deviation from baseline)		* '''R time''': Time to initial clot formation (that is, amplitude deviation from baseline)

Mikael Häggström: delinked

2022-10-28T18:47:49Z

delinked

← Older revision		Revision as of 14:47, 28 October 2022
Line 26:		Line 26:
	\| Thrombosis \|\| [[File:Thromboelastography in thrombosis.png\|170px]] \|\| Anticoagulant		\| Thrombosis \|\| [[File:Thromboelastography in thrombosis.png\|170px]] \|\| Anticoagulant
	\|-		\|-
	\| Primary fibrinolysis \|\| [[File:Thromboelastography in primary fibrinolysis.png\|170px]] \|\| Antifibrinolytics or [[tranexamic acid]]		\| Primary fibrinolysis \|\| [[File:Thromboelastography in primary fibrinolysis.png\|170px]] \|\| Antifibrinolytics or tranexamic acid
	\|-		\|-
	\| Secondary fibrinolysis \|\| [[File:Thromboelastography in secondary fibrinolysis.png\|170px]] \|\| Treating [[disseminated intravascular coagulation]]		\| Secondary fibrinolysis \|\| [[File:Thromboelastography in secondary fibrinolysis.png\|170px]] \|\| Treating disseminated intravascular coagulation
	\|}		\|}
	{{Bottom}}		{{Bottom}}

Mikael Häggström: +Normal

2022-10-28T18:47:22Z

+Normal

← Older revision		Revision as of 14:47, 28 October 2022
Line 4:		Line 4:
	}}		}}
	==Interpretation==		==Interpretation==
			[[Image:Thromboelastography parameters.png\|thumb\|300px\|Normal thromboelastogram with parameters.]]
			Parameters derived from thromboelastography are mainly:<ref name="pmid32988649">{{cite journal\| author=Tyler PD, Yang LM, Snider SB, Lerner AB, Aird WC, Shapiro NI\| title=New Uses for Thromboelastography and Other Forms of Viscoelastic Monitoring in the Emergency Department: A Narrative Review. \| journal=Ann Emerg Med \| year= 2021 \| volume= 77 \| issue= 3 \| pages= 357–366 \| pmid=32988649 \| doi=10.1016/j.annemergmed.2020.07.026 \| pmc= \| doi-access=free }} </ref>
			* '''R time''': Time to initial clot formation (that is, amplitude deviation from baseline)
			* '''K time''': Time from initial clot formation until reaching 20 mm in amplitude
			* '''Alpha angle (α)''': Angle between the baseline at initial clot formation, and a tangent line that intersects the tracing curve.
			* '''Maximum amplitude (MA)''': Maximum deviation of tracing to baseline.
			* '''A<sub>30</sub>''': Amplitude 30 minutes after reaching maximum amplitude.

	Following are examples of thromboelastography patterns and recommended treatments.<ref>{{cite journal\| author=Collins S, MacIntyre C, Hewer I\| title=Thromboelastography: Clinical Application, Interpretation, and Transfusion Management. \| journal=AANA J \| year= 2016 \| volume= 84 \| issue= 2 \| pages= 129–34 \| pmid=27311154 \| doi= \| pmc= \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27311154 }}</ref><ref>{{cite journal\| author=Kreitzer NP, Bonomo J, Kanter D, Zammit C\| title=Review of Thromboelastography in Neurocritical Care. \| journal=Neurocrit Care \| year= 2015 \| volume= 23 \| issue= 3 \| pages= 427–33 \| pmid=26275677 \| doi=10.1007/s12028-015-0187-9 \| pmc= \| s2cid=29854774 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26275677 }}</ref>		Following are examples of thromboelastography patterns and recommended treatments.<ref>{{cite journal\| author=Collins S, MacIntyre C, Hewer I\| title=Thromboelastography: Clinical Application, Interpretation, and Transfusion Management. \| journal=AANA J \| year= 2016 \| volume= 84 \| issue= 2 \| pages= 129–34 \| pmid=27311154 \| doi= \| pmc= \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27311154 }}</ref><ref>{{cite journal\| author=Kreitzer NP, Bonomo J, Kanter D, Zammit C\| title=Review of Thromboelastography in Neurocritical Care. \| journal=Neurocrit Care \| year= 2015 \| volume= 23 \| issue= 3 \| pages= 427–33 \| pmid=26275677 \| doi=10.1007/s12028-015-0187-9 \| pmc= \| s2cid=29854774 \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26275677 }}</ref>
	{\|class=wikitable		{\|class=wikitable

Mikael Häggström: Thromboelastography

2022-10-28T16:53:14Z

Thromboelastography

New page

{{Top
|author1={{MH top}}
|author2=
}}
==Interpretation==
Following are examples of thromboelastography patterns and recommended treatments.<ref>{{cite journal| author=Collins S, MacIntyre C, Hewer I| title=Thromboelastography: Clinical Application, Interpretation, and Transfusion Management. | journal=AANA J | year= 2016 | volume= 84 | issue= 2 | pages= 129–34 | pmid=27311154 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27311154 }}</ref><ref>{{cite journal| author=Kreitzer NP, Bonomo J, Kanter D, Zammit C| title=Review of Thromboelastography in Neurocritical Care. | journal=Neurocrit Care | year= 2015 | volume= 23 | issue= 3 | pages= 427–33 | pmid=26275677 | doi=10.1007/s12028-015-0187-9 | pmc= | s2cid=29854774 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26275677 }}</ref>
{|class=wikitable
! Condition !! Appearance !! Main treatment
|-
| Normal || [[File:Normal thromboelastography.png|170px]] ||
|-
| Hemodilution or clotting factor deficiency || [[File:Thromboelastography in hemodilution or clotting factor deficiency.png|170px]] || Fresh frozen plasma
|-
| Fibrinogen deficiency || [[File:Thromboelastography in fibrinogen deficiency.png|170px]] || Cryoprecipitate
|-
| Low or dysfunctional platelets || [[File:Thromboelastography in low or dysfunctional platelets.png|170px]] || Platelets
|-
| Thrombosis || [[File:Thromboelastography in thrombosis.png|170px]] || Anticoagulant
|-
| Primary fibrinolysis || [[File:Thromboelastography in primary fibrinolysis.png|170px]] || Antifibrinolytics or [[tranexamic acid]]
|-
| Secondary fibrinolysis || [[File:Thromboelastography in secondary fibrinolysis.png|170px]] || Treating [[disseminated intravascular coagulation]]
|}
{{Bottom}}